IT-guided HIV screening and prevention in dental clinics
Official title: Effectiveness of Comprehensive Ending the Epidemic (ETE) Interventions in the Dental Setting
Run by Columbia University · NCT06890988 · Data updated 2026-11-12
This project will test whether an electronic alert plus either the usual dental team or an added care navigator helps dental teams offer HIV testing and prevention to dental patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | Columbia University Academic / other |
| Locations | 3 sites (New York, New York and 2 other locations) |
| Status | Recruiting |
| Started | March 31, 2025 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT06890988 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are dental team members (providers, hygienists, dental assistants, or care navigators) with direct patient contact at one of the three participating New York City dental programs who can provide written informed consent.
✕Probably not a fit
Patients who do not receive care at the participating clinics, who decline HIV testing, or who live outside these sites are unlikely to benefit directly from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study uses an electronic Best Practice Alert (BPA) linked to an order set to prompt dental residents and staff to offer routine HIV screening and PrEP education during dental visits. Three urban general dentistry programs in New York City will be randomized in a crossover design to periods with the standard dental care team and periods with an enhanced team that includes a dedicated care navigator. Investigators will compare offer and uptake rates of HIV testing, linkage to results and prevention services, and implementation outcomes such as acceptability and feasibility among dental team members. Data will be collected from electronic health records and staff feedback to determine which model better supports consistent delivery of HIV prevention and care practices.
Why it matters
Potential benefit: If successful, this approach could increase routine HIV screening in dental settings and speed diagnosis and linkage to prevention and care, including PrEP.
How similar studies have gone: Electronic clinical decision support and opt-out HIV screening have increased testing in medical settings, but integration into dental clinics and the specific addition of care navigators is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Member of the Dental Team (Provider, Hygienist, Dental Assistant, Care Navigator) at one of the randomized sites with direct patient contact * Able to provide written informed consent. Exclusion Criteria: \- Inability to provide written informed consent.
Where it's running
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States Recruiting -
Weill Cornell Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States Not yet recruiting -
NYP-Queens
Queens, New York, United States Not yet recruiting
Study contacts
- Study coordinator: Michael Yin, MD, MS
- Email: mty4@cumc.columbia.edu
- Phone: 212-305-7185
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap
This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.
-
Weekly long-acting HIV-1 meds switch for people with undetectable virus
This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.
-
HIV in Hong Kong: patterns, transmission, and burden over time
This project tests how HIV-1 infections in Hong Kong have changed over several years by following newly diagnosed adults and analyzing their subtypes, transmission links, and community burden.
-
GS-0415 safety and PK in people with HIV on ART
This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.
-
Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy
This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.
-
RNA-based vaccine BNT168 safety and immune response in adults with or without HIV
A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.